Trastuzumab

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab (coding:ncit:C1647)

RxNorm: trastuzumab (coding:rxcui:224905, coding:omop:1387104)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (2) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
EMA (4) FDA (4) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (8) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
EMA (1) FDA (8) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (1) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
EMA (2) FDA (4) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
EMA (2) FDA (2) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
EMA (3) HER2-positive Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (3) ERBB2 amplification Invasive Breast Carcinoma Docetaxel, Trastuzumab
EMA (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) HER2-positive Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Trastuzumab
EMA (2) ERBB2 amplification Invasive Breast Carcinoma Paclitaxel, Trastuzumab
EMA (1) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
EMA (1) ERBB2 amplification Invasive Breast Carcinoma Doxorubicin, Paclitaxel, Trastuzumab
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) HER2-positive Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Capecitabine, Cisplatin, Trastuzumab
EMA (1) ERBB2 amplification Esophagogastric Adenocarcinoma Cisplatin, Fluorouracil, Trastuzumab
EMA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab, Trastuzumab
EMA (1) ER positive, HER2-positive, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR negative Invasive Breast Carcinoma Lapatinib, Trastuzumab
EMA (1) ER positive, ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ER positive, ERBB2 amplification Invasive Breast Carcinoma Anastrozole, Trastuzumab
EMA (1) ERBB2 amplification, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
FDA (2) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
EMA (1) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Anastrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Exemestane, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Trastuzumab
FDA (2) ER positive, HER2-positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib, Pertuzumab, Trastuzumab
FDA (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab deruxtecan